Story

BlackRock Shares Surge on Record AUM and Strong Q2 Earnings Beat

ENTHMSVIIDZHZH-TWJAKOHI
Jul 15, 20261 min read
BlackRock Shares Surge on Record AUM and Strong Q2 Earnings Beat

Summary

BlackRock stock jumped in pre-market trading after the asset manager reported second-quarter earnings and revenue that surpassed expectations, with assets under management crossing the $15 trillion mark for the first time.

Text size
Background

BlackRock (BLK) shares surged 3.9% in pre-open trading after the world's largest asset manager announced second-quarter financial results that significantly exceeded analyst forecasts, driven by strong client inflows and a new milestone in assets under management.

Earnings Beat and Record AUM

The firm reported adjusted earnings per share of $13.91, well above the consensus estimate of approximately $12.57. Quarterly revenue reached $7.08 billion, a 31% increase from the same period a year ago and ahead of the anticipated $6.72 billion.

The most significant achievement was the growth in assets under management (AUM), which surpassed $15 trillion for the first time. Key figures from the Q2 2026 report include:

  • Total AUM: $15.34 trillion, up from $12.53 trillion a year prior.
  • Quarterly Net Inflows: $192 billion.
  • Actively Managed Inflows: $53 billion.

Strong Inflows Signal Investor Confidence

Sample IUX Markets – In-articleAd

The substantial $192 billion in net client inflows during the quarter was a primary driver of the AUM growth. According to the report, investors allocated significant capital to both the company's popular exchange-traded fund (ETF) platform and its actively managed strategies.

The strong performance follows recent price target upgrades from analysts at firms including Keefe Bruyette and Evercore ISI, signaling growing optimism about the company's prospects ahead of the earnings release.

Market Context

BlackRock's significant pre-market rally stood in contrast to the broader market's more modest gains, with S&P 500 futures up 0.2% and Nasdaq futures rising 0.5%. This divergence underscores that the stock's sharp move was overwhelmingly driven by its strong company-specific results rather than a wider market trend.

Read next

More on Stocks
Shenzhen-Listed Jingxin Pharmaceutical Refiles for Hong Kong IPO

Stocks

Shenzhen-Listed Jingxin Pharmaceutical Refiles for Hong Kong IPO

Sep 20, 2026

Zhejiang Jingxin Pharmaceutical Co., Ltd. (002020.SZ) has resubmitted its application for a main board listing on the Hong Kong Stock Exchange, aiming to secure a dual listing to access international capital. The company specializes in drugs for central nervous system and cardiovascular diseases.

Back to latest news

LATEST